Canaccord Genuity Group Has Lowered Expectations for Teladoc Health (NYSE:TDOC) Stock Price

Teladoc Health (NYSE:TDOC) had its price target dropped by analysts at Canaccord Genuity Group from $12.00 to $10.00 in a report issued on Thursday,Benzinga reports. The firm currently has a “buy” rating on the health services provider’s stock. Canaccord Genuity Group’s target price suggests a potential upside of 86.71% from the company’s previous close.

A number of other brokerages have also weighed in on TDOC. BMO Capital Markets dropped their target price on shares of Teladoc Health from $8.00 to $5.00 and set a “market perform” rating for the company in a research report on Thursday. Bank of America upgraded shares of Teladoc Health from a “neutral” rating to a “buy” rating and set a $7.00 price target on the stock in a research note on Thursday. Weiss Ratings reissued a “sell (e+)” rating on shares of Teladoc Health in a report on Monday, December 29th. Wells Fargo & Company reduced their target price on Teladoc Health from $8.00 to $6.00 and set an “equal weight” rating on the stock in a report on Thursday. Finally, Zacks Research downgraded Teladoc Health from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 10th. Four analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Teladoc Health currently has a consensus rating of “Hold” and a consensus price target of $7.80.

Teladoc Health Price Performance

Shares of NYSE TDOC traded up $0.71 during mid-day trading on Thursday, reaching $5.36. The company’s stock had a trading volume of 19,458,467 shares, compared to its average volume of 6,899,794. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.70 and a quick ratio of 2.60. Teladoc Health has a 52 week low of $4.40 and a 52 week high of $10.02. The stock has a fifty day moving average of $6.06 and a two-hundred day moving average of $7.22. The firm has a market capitalization of $950.53 million, a PE ratio of -4.18 and a beta of 2.12.

Teladoc Health (NYSE:TDOC) last posted its quarterly earnings results on Wednesday, February 25th. The health services provider reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.05. Teladoc Health had a negative return on equity of 10.59% and a negative net margin of 8.84%.The company had revenue of $642.27 million for the quarter, compared to analysts’ expectations of $635.33 million. During the same period in the previous year, the firm earned ($0.28) EPS. The firm’s revenue was up .3% compared to the same quarter last year. Teladoc Health has set its Q1 2026 guidance at -0.450–0.350 EPS and its FY 2026 guidance at -1.100–0.700 EPS. As a group, sell-side analysts anticipate that Teladoc Health will post -1.16 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Carlos Nueno sold 3,897 shares of Teladoc Health stock in a transaction that occurred on Tuesday, December 2nd. The stock was sold at an average price of $7.49, for a total value of $29,188.53. Following the completion of the transaction, the insider owned 27,175 shares in the company, valued at approximately $203,540.75. The trade was a 12.54% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Adam C. Vandervoort sold 5,720 shares of the stock in a transaction on Tuesday, December 2nd. The shares were sold at an average price of $7.49, for a total value of $42,842.80. Following the sale, the insider owned 80,732 shares in the company, valued at $604,682.68. The trade was a 6.62% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 33,288 shares of company stock valued at $251,684. Insiders own 0.58% of the company’s stock.

Hedge Funds Weigh In On Teladoc Health

Large investors have recently made changes to their positions in the company. Allianz Asset Management GmbH grew its stake in shares of Teladoc Health by 189.2% during the third quarter. Allianz Asset Management GmbH now owns 1,619,391 shares of the health services provider’s stock valued at $12,518,000 after buying an additional 1,059,458 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new position in Teladoc Health during the 2nd quarter valued at $2,722,000. Jupiter Asset Management Ltd. bought a new position in Teladoc Health in the 3rd quarter valued at $7,576,000. Banco Bilbao Vizcaya Argentaria S.A. grew its position in Teladoc Health by 23.1% in the 2nd quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 212,933 shares of the health services provider’s stock valued at $1,841,000 after acquiring an additional 39,956 shares during the last quarter. Finally, Empowered Funds LLC purchased a new stake in Teladoc Health in the second quarter worth $5,040,000. 76.82% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Teladoc Health

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Q4 results topped expectations: Teladoc posted a narrower-than-expected GAAP loss (EPS -$0.14 vs. -$0.19 consensus) and revenue of $642.3M slightly above estimates, driven by international and Integrated Care strength which helped offset BetterHelp weakness. Teladoc Tops Q4 Earnings
• Positive Sentiment: Bank of America upgraded TDOC from Neutral to Buy and set a $7 price target, signaling conviction from a large shop and providing buy-side momentum. BofA Upgrade
• Positive Sentiment: Piper Sandler reaffirmed an Overweight rating with a $9 price target (albeit reduced from $12), underscoring that some sell-side analysts still see meaningful upside based on recovery potential. Piper Sandler Note
• Neutral Sentiment: Company provided forward revenue range for 2026 ($2.47B–$2.59B) and emphasized investments in AI, insurance partnerships, and international expansion — strategic positives, but longer‑term and already partly baked into expectations. 2026 Revenue Projection
• Neutral Sentiment: Investors can review the full earnings call transcript and slide deck for detail on segment trends and cost actions; useful for modeling but not immediate catalysts by themselves. Earnings Call Transcript Slide Deck
• Negative Sentiment: Guidance was weaker than Street expectations: Q1 EPS guide (-$0.45 to -$0.35 vs. est -$0.28) and Q1 revenue guide ($598M–$620M vs. est ~$633M) came in below consensus, and FY EPS range (-$1.10 to -$0.70) is wider/poorer than modeled — a primary reason for intra‑day pressure before buyers stepped in. Earnings & Guidance
• Negative Sentiment: Several firms trimmed price targets and lowered ratings (Cowen to $6 Hold, BMO to $5 Market Perform, Wells Fargo to $6 Equal Weight, Stifel to $6 Hold), signaling more cautious near‑term views from parts of the sell side and creating downward pressure despite the beat. Analyst PT Cuts BMO Note

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.